Influence of plasma estrogen levels on the length of the disease-free interval in postmenopausal women with breast cancer
- 41 Downloads
The influence of plasma estrogen levels on disease-free interval (time from primary treatment to first relapse, DFI) in breast cancer patients is not known. Any relation between plasma estrogens and the outcome in breast cancer patients may have implications considering use of hormone replacement therapy (HRT) in patients treated for breast cancer. We measured plasma estradiol (E2), estrone (E1), and estrone sulfate (E1S) in 92 postmenopausal women with breast cancer relapse and correlated plasma estrogen levels to the length of their disease-free interval (DFI1) and the length of the DFI in the subgroup of patients in whom this extended a time period of more than 2 years (DFI2). The length of DFI2 correlated negatively to plasma level of E1S (p < 0.025) and E2 (p < 0.05) and to the E2/E1 and E1S/E1 ratios (p < 0.05), while the length of DFI1 correlated negatively to plasma level of E1S (p < 0.025) and the E1S/E1 ratio (p < 0.005). We also analyzed for possible correlations between DFIs and plasma estrogen levels in subgroups based on tumor stage at diagnosis and previous therapy. In general, these subgroup analyses revealed negative correlations of statistical significance or borderline significance between the DFI1 and DFI2 and E2 and the E2/E1 ratio and non-significant negative correlations between plasma levels of E1S and DFI1 and DFI2. In particular, strong negative correlations between plasma estrogen levels and the length of DFI1 and DFI2 were found among patients responding to first line endocrine treatment for relapse and among patients with primar stage III tumors. Our findings suggest plasma E2 and E1S to stimulate the growth of micrometastases in patients treated for breast cancer.
Key wordsbreast cancer disease-free interval estrogens
Unable to display preview. Download preview PDF.
- 1.Beatson GT: On the treatment of inoperable cases of carcinoma of the mamma. Suggestions for a new method of treatment, with illustrative cases. Lancet 2: 104–107, 1896Google Scholar
- 2.Furr BJA, Jordan VC: The pharmacology and clinical uses of tamoxifen. Pharmac Ther 25: 127–205, 1984Google Scholar
- 3.Santen RJ, Manni A, Harvey H, Redmond C: Endocrine treatment of breast cancer in women. Endocrine Rev 11: 221–265, 1990Google Scholar
- 5.Early Breast Cancer Trialist Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Part 1. Lancet 339: 1–15, 1992Google Scholar
- 7.Cobleigh MA, Berris RF, Bush T, Davidson NE, Robert NJ, Sparano JA, Tormey DC, Wood WC: Estrogen replacement therapy in breast cancer survivors. J Am Med Assoc 272: 540–545, 1994Google Scholar
- 9.Rose C, Theilade K, Boesen E, Salimtschik M, Dombernowsky P, Brünner N, Kjaer M, Mouridsen HT: Treatment of advanced breast cancer with tamoxifen: evaluation of the dose-response relationship at two dose levels. Breast Cancer Res Treat 2: 395–400, 1982Google Scholar
- 10.Lønning PE, Helle S-I, Johannessen DC, Adlercreutz H, Lien EA, Tally M, Ekse D, Fotsis T, Anker GB, Hall K: Relations between sex hormones, sex hormone binding globulin, insulin-like growth factor-I and insulin-like growth factor binding protein-1 in postmenopausal breast cancer patients. Clin Endocrinol 42: 23–30, 1995Google Scholar
- 14.Fracchia AA, Farrow JH, DePalo AJ, Connolly DP, Huvos AG: Castration for primary inoperable or recurrent breast carcinoma. Surg Gyn Obstet 128: 1226–1234, 1969Google Scholar
- 21.Tait GH, Newton CJ, Reed MJ, James VHT: Multiple forms of 17β-hydroxysteroid oxidoreductase in human breast tissue. J Molec Endocr 2: 71–80, 1989Google Scholar
- 23.De Nosaquo N: Androgens and estrogens in the treatment of disseminated mammary cancer. J Am Med Assoc 172: 1271–1283, 1960Google Scholar